Detalles de la búsqueda
1.
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.
Am J Drug Alcohol Abuse
; 49(1): 109-122, 2023 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36630319
2.
Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
Adv Ther
; 39(10): 4821-4835, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36002761
3.
Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
J Clin Psychiatry
; 83(6)2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36198061
4.
Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
Adv Ther
; 40(1): 391, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36315340
Resultados
1 -
4
de 4
1
Próxima >
>>